UCB Keppra
Brand and Performance Dual Growth
UCB Keppra
Brand and Performance Dual Growth

Background Objectives

Epilepsy patients lack understanding of their condition and have limited knowledge about the disease and medication. Currently, major platforms do not recommend the use of Levetiracetam tablets for individuals of childbearing age, resulting in a lack of awareness among the target audience that the original Levetiracetam tablets can be used for epilepsy treatment in patients of childbearing age. Based on insights from big data and the brand's current situation, Keppra aims to educate the target audience about the disease, enhance awareness of Levetiracetam tablets and the original medication, and deepen understanding of the brand.

Core Insights

The information on various platforms regarding Levetiracetam tablets is outdated, leading patients to hold a deep-seated misconception that Levetiracetam tablets are not suitable for women of childbearing age. Additionally, there is a lack of clear understanding regarding the distinction between the original medication and generic drugs.
Faced with challenges arising from outdated online platform information, insufficient patient awareness, and compliance restrictions associated with Keppra as a prescription drug, how should USB respond to these challenges?
Solution
Our communication strategy is fortified with technology to bridge the gap in patient awareness. Leveraging medical media to target and gather traffic, we utilize platform influence and influencer effects to reshape the outdated perception of Levetiracetam tablets. Coupled with persistent penetration through search results, and the dissemination of high-quality video content, we emphasize the medicinal value of the brand, effectively aiding USB in providing comprehensive disease education for epilepsy patients.

TOP